AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

AML.AU AEON METALS LTD

Not Yet Opened 05-31 16:12:00 AEST

0.01

+0.00

0.00%

High0.01	Low0.01	Vol0.00
Open0.01	D1 Closing0.01	Amplitude0.00%
Mkt Cap8.77M	Tradable Cap3.47M	Total Shares1.10B
T/O0.00	T/O Rate0.00%	Tradable Shares433.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AML.AU","market":"AU","secType":"STK","nameCN":"AEON METALS LTD","latestPrice":0.008,"timestamp":1717135920000,"preClose":0.008,"halted":0,"volume":0,"delay":0,"nameEN":"AEON METALS LTD","floatShares":433235140,"shares":1096400622,"eps":-0.007335,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-31 16:12:00 AEST","open":0.008,"high":0.008,"low":0.008,"amount":0,"amplitude":0,"askPrice":0.009,"askSize":219984,"bidPrice":0.007,"bidSize":1791109,"shortable":3,"etf":0,"ttmEps":-0.007335,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1717372800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1717113600000,1717135200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/AML.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2437404657","title":"BUZZ-Australia's Aeon Metals set for best day in 14 years on land access agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2437404657","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437404657?lang=en_us&edition=fundamental","pubTime":"2024-05-22 09:36","pubTimestamp":1716341768,"startTime":"0","endTime":"0","summary":"** Shares of Aeon Metals    jump 57.1% to A$0.011, set for best day since Jan. 6, 2010, if gains hold   ** Mineral explorer says traditional land owners have agreed terms for a new Cultural Heritage Protection Agreement for land access Walford Creek in Queensland   ** Says, agreement allows co to recommence activities at Walford Creek   ** AML stock down 36.4% YTD, as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435329587","title":"Press Release: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435329587","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435329587?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:30","pubTimestamp":1715599800,"startTime":"0","endTime":"0","summary":"--     Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine  achieves CRc rate of 62%  in 1 and 2 line AML subjects . --     Also announced MB-106 reaches 20 subjects enrolled. --     Company to host conference call and webcast today, Monday, May 13 at 8:30 AM ET. \"We recently hosted a virtual AML Clinical Day featuring renowned KOLs, Dr. Martin Tallman and Dr. Michael Andreeff. It was great to hear their support of and thoughts on Annamycin's recent developments in AML. You can hear that discussion here. Combined with the encouraging Annamycin data demonstrated to date and the positive feedback from the KOLs, we continue to believe that our results in 2 line subjects fill a significant unmet need. We believe this is supported by the exceptional  CRc rate demonstrated by AnnAraC in 2 line patients, which substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2 line AML. We believe ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434500047","title":"Press Release: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2434500047","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434500047?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284860,"startTime":"0","endTime":"0","summary":"Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024. Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025. SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024  -- eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors  for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.\"We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the ZF doublet dose escalation, and ongoing assessment of increasing doses in the ZFA triplet,\" said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \"We are highly encouraged with the safety profile and activity already reported for the ZFA triplet, in particular the 7.4 month mPFS in heavily pre-treated patients, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433661401","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2433661401","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433661401?lang=en_us&edition=fundamental","pubTime":"2024-05-07 00:03","pubTimestamp":1715011380,"startTime":"0","endTime":"0","summary":"-- Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial. -- Company planning to request an End-of-Phase II meeting with the FDA to. discuss plans for a registrational Phase III trial in BPD. grant in the EU and Korea for patent application covering the use of. Dr Carlos Buesa, Oryzon's Chief Executive Officer, said: \"Oryzon continued with a strong path in its clinical programs in the first quarter. In CNS, following presentation in January of topline data from our Phase IIb PORTICO trial evaluating vafidemstat as a treatment for Borderline Personality Disorder , we are finalizing the full data set analysis. The company is preparing the request of an End-of-Phase II meeting with the FDA to discuss the design of a Phase III. Our Phase IIb trial with vafidemstat in schizophrenia, EVOLUTION, has also continued to enroll patients. Importantly, we have received from the European Patent Office  an \"intention to grant\" communication for Oryzon's European patent application ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433447541","title":"Press Release: GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433447541","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433447541?lang=en_us&edition=fundamental","pubTime":"2024-05-06 18:00","pubTimestamp":1714989600,"startTime":"0","endTime":"0","summary":"--  Study of uproleselan combined with chemotherapy did not meet its. primary endpoint of overall survival in the intent to treat population. --  Adverse events were consistent with known side effect profiles of. --  Comprehensive data analysis with medical, statistical, and regulatory. experts underway and will be shared as appropriate; company will submit. results for presentation at an upcoming medical meeting. --  National Cancer Institute  Phase 2/3 study in newly diagnosed AML. GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.The NCI and the Alliance for Clinical Trials i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2430745706","title":"Nkarta: Down 50% Since March With A Clinical Catalyst Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2430745706","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430745706?lang=en_us&edition=fundamental","pubTime":"2024-04-27 22:27","pubTimestamp":1714228020,"startTime":"0","endTime":"0","summary":"NKTX is now down over 50% from its March 2024 highs.The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease.NKTX has already produced some data wi","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412352157/image_1412352157.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412352157/image_1412352157.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687011-nkarta-down-50-percent-since-march-with-a-clinical-catalyst-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2430202124","title":"Cobalt Miners News For The Month Of April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2430202124","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430202124?lang=en_us&edition=fundamental","pubTime":"2024-04-25 16:31","pubTimestamp":1714033908,"startTime":"0","endTime":"0","summary":"Cobalt spot prices were slightly lower for the month. LME inventory was unchanged for the month.Cobalt market news - S&P Global - Cobalt metal market was seen oversupplied through Q2 as demand subdued","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320518434/image_1320518434.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320518434/image_1320518434.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686002-cobalt-miners-news-for-the-month-of-april-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2428510511","title":"Jazz Pharmaceuticals: Cheap But Complicated","url":"https://stock-news.laohu8.com/highlight/detail?id=2428510511","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428510511?lang=en_us&edition=fundamental","pubTime":"2024-04-19 01:26","pubTimestamp":1713461198,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy.The company's narcolepsy franchise is facing competition from A","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149615583/image_149615583.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149615583/image_149615583.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4684510-jazz-pharmaceuticals-cheap-but-complicated","is_publish_highlight":false,"gpt_icon":0},{"id":"2428073593","title":"HOLO, SNTG and LRHC are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2428073593","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428073593?lang=en_us&edition=fundamental","pubTime":"2024-04-18 20:40","pubTimestamp":1713444055,"startTime":"0","endTime":"0","summary":"Gainers: Bio-Path Holdings (BPTH) +61% Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090954-holo-sntg-and-lrhc-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aeonmetals.com.au","stockEarnings":[{"period":"1week","weight":-0.1111},{"period":"1month","weight":0.3333},{"period":"3month","weight":0.1429},{"period":"6month","weight":-0.2727},{"period":"1year","weight":-0.5556},{"period":"ytd","weight":-0.2727}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":0.0109},{"period":"3month","weight":0.0709},{"period":"6month","weight":0.1157},{"period":"1year","weight":0.1453},{"period":"ytd","weight":0.1047}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Aeon Metals Limited explores for and develops mineral properties in Australia. The company primarily explores for copper, cobalt, gold, lead, zinc, molybdenum, silver, and base metal deposits. Its flagship property is the Walford Creek project comprising 4 exploration permits covering an area of 211.6 square kilometers located in northwest Queensland. The company was formerly known as Aussie Q Resources Limited and changed its name to Aeon Metals Limited in August 2012. Aeon Metals Limited was incorporated in 2006 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.068448},{"month":2,"riseRate":0.411765,"avgChangeRate":-0.014054},{"month":3,"riseRate":0.294118,"avgChangeRate":-0.051354},{"month":4,"riseRate":0.529412,"avgChangeRate":0.117322},{"month":5,"riseRate":0.125,"avgChangeRate":-0.127824},{"month":6,"riseRate":0.588235,"avgChangeRate":0.21765},{"month":7,"riseRate":0.352941,"avgChangeRate":-0.046612},{"month":8,"riseRate":0.588235,"avgChangeRate":0.027533},{"month":9,"riseRate":0.235294,"avgChangeRate":-0.101363},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.024502},{"month":11,"riseRate":0.352941,"avgChangeRate":-0.009087},{"month":12,"riseRate":0.411765,"avgChangeRate":0.201763}],"exchange":"ASX","name":"AEON METALS LTD","nameEN":"AEON METALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AEON METALS LTD(AML.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AEON METALS LTD,AML.AU,AEON METALS LTD股票,AEON METALS LTD股票老虎,AEON METALS LTD股票老虎国际,AEON METALS LTD行情,AEON METALS LTD股票行情,AEON METALS LTD股价,AEON METALS LTD股市,AEON METALS LTD股票价格,AEON METALS LTD股票交易,AEON METALS LTD股票购买,AEON METALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AEON METALS LTD(AML.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction